A clinical‑stage biotechnology company focused on developing therapies for neurological disorders, with research programs targeting conditions such as hereditary ataxias and related rare diseases. The firm’s value is largely tied to clinical trial progress, intellectual property, and regulatory mile...
No congressional trades have been disclosed for Ataxis PLC (ATXS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.